BUENA, NJ May 3, 2007 - IGI, INC. (AMEX: IG) announced the grant of a US patent (# 7,205,006) for encapsulated Mahonia Aquifolium Extract, Extraction Process and Pharmaceutical composition containing the same. The patent has been jointly issued to IGI and Prime Pharmaceutical. Apollo Pharmaceutical holds the exclusive worldwide licensing rights for all potential commercial applications of Psorberine.
Apollo Pharmaceutical reported positive results from a 200 patient, 12 week, randomized, double blind, and a placebo controlled study to assess the efficacy and safety of Relieva™ topical cream in patients with mild to moderate psoriasis. Psoriasis is a common skin disorder that affects approximately 9 million people in North America alone.
The Relieva™ cream, lotion and shampoo products were developed by scientists at IGI using the Novasome® technology to encapsulate and deliver Mahonia Aquifolium (Psorberine) to Psoriatic plaque.
IGI is exclusively manufacturing these products for Apollo which are available for purchase at www.relieva.com and select pharmacies and physician's offices across Canada and the US.
"This further attests the capability of Novasome® encapsulation technology to enhance the delivery of active molecules to the skin," said Rajiv Mathur, President and CEO of IGI, Inc.
Apollo Pharmaceutical Inc. (www.apollorx.net) is an exciting new healthcare company with a remarkable combination of talented people and advanced technologies, with a goal of bringing to market uniquely effective dermatology products.
This report contains forward-looking statements relating to IGI's hopes and expectations for the future. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, words such as "will," "possible," "one time," "provides an opportunity," "continue" and similar expressions are intended to identify forward-looking statements. Such statements involve a number of risks and uncertainties and actual future events and results could differ materially from those indicated by such forward-looking statements due to general economic conditions, and the risk factors detailed in IGI's periodic reports and registration statements filed with the Securities and Exchange Commission.
Contact:
Rajiv Mathur President & Chief Executive Officer IGI, Inc. 856-697-1441 ext. 102 www.askigi.com